Juno Therapeutics Inc (JUNO) was Initiated by Raymond James to “Outperform” and the brokerage firm has set the Price Target at $52. Raymond James advised their investors in a research report released on Jun 2, 2016.
Many Wall Street Analysts have commented on Juno Therapeutics Inc. Company shares were Reiterated by Maxim Group on Apr 11, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $78 .
On the company’s financial health, Juno Therapeutics Inc reported $-0.78 EPS for the quarter, missing the analyst consensus estimate by $ -0.26 based on the information available during the earnings call on May 9, 2016. Analyst had a consensus of $-0.52. The company had revenue of $9.80 million for the quarter, compared to analysts expectations of $3.15 million. During the same quarter in the previous year, the company posted $-0.30 EPS.
Juno Therapeutics Inc closed down -1.04 points or -2.39% at $42.39 with 9,45,749 shares getting traded on Wednesday. Post opening the session at $43, the shares hit an intraday low of $42.13 and an intraday high of $43.83 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on May 20, 2016, Bernard J Cassidy (General Counsel & Secretary) sold 3,116 shares at $39.23 per share price. According to the SEC, on May 20, 2016, Richard Klausner (director) sold 12,000 shares at $40.00 per share price. On Mar 30, 2016, Anthony B Evnin (director) purchased 8,000 shares at $36.58 per share price, according to the Form-4 filing with the securities and exchange commission.
Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.